N-imidazolyl derivatives of substituted alkoxyimino tetrahydronaphthalenes and chromans
申请人:PHARMACIA S.p.A.
公开号:EP0499444A1
公开(公告)日:1992-08-19
The invention provides new imidazole containing alkoxyimino derivatives of tetrahydronaphthalene and chroman of general formula (I)
wherein
Z is -CH₂-or-O-;
m is an integer of 1 to 4;
n is zero or 1;
T is a straight or branched, saturated or unsaturatrd C₁-C₆ hydrocarbon chain, or a phenylene radical;
A is a bond or a divalent group consisting of-Si(R′R˝)-; -O-CH₂-,-CF₃-,C(R′R˝)-,vinylene or isopropenylene, wherein each of R′ and R˝being the same or different is hydrogen or C₁-C₄ alkyl;
R is hydrogen or C₁-C₄ alkyl;
R₁ and R₂, being the same, are hydrogen or methyl, or one of R₁ and R₂ is hydrogen and the other is
a) a C₁-C₈ alkyl group;
b) a C₅-C₈ cycloalkyl or C₅-C₈ cycloalkyl-C₁-C₄ alkyl group, wherein the cycloalkyl group or moiety is unsubstituted or substituted by 1 to 4 C₁-C₄ alkyl groups; or
c) an aryl or aryl-C₁-C₄ alkyl group, wherein the aryl group or the aryl moiety is unsubstituted or substituted by 1 to 4 substituents independently chosen from halogen, hydroxy, C₁-C₄ alkyl, trihalo-C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio and C₁-C₄ alkylsulfonyl;
R₃ is hydrogen or a substituent chosen from halogen, hydroxy, C₁-C₄ alkyl, trihalo-C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio and C₁-C₄ alkylsulfonyl;
R₄ is an -OR₅, or -N(R₅ R₆)group, wherein each of R₅ and R₆ independently is hydrogen, C₁-C₆ alkyl, phenyl or benzyl;
and the pharmaceutically acceptable salts thereof, which are useful in the treatment of a disease state in which an anhancement of TxA₂ synthesis exerts a pathogenic effect.
本发明提供了通式(I)为四氢萘和铬烷的含烷氧基亚氨基的新咪唑衍生物
其中
Z 是-CH₂-或-O-;
m 是 1 至 4 的整数
n 为 0 或 1;
T 是直链或支链、饱和或不饱和 C₁-C₆烃链,或亚苯基;
A 是键或由下列组成的二价基团:-Si(R′R˝)-;-O-CH₂-、-CF₃-、C(R′R˝)-、乙烯基或异亚丙烯基,其中 R′和 R˝ 不论相同或不同均为氢或 C₁-C₄ 烷基;
R 是氢或 C₁-C₄ 烷基;
R₁和R₂若相同,则为氢或甲基,或R₁和R₂中的一个为氢,另一个为
a) C₁-C₈ 烷基;
b) C₅-C₈ 环烷基或 C₅-C₈ 环烷基-C₁-C₄ 烷基,其中环烷基或分子未被取代或被 1 至 4 个 C₁-C₄ 烷基取代;或
c) 芳基或芳基-C₁-C₄烷基,其中芳基或芳基分子未被取代或被 1 至 4 个独立选自卤素的取代基取代、羟基、C₁-C₄ 烷基、三卤代-C₁-C₄ 烷基、C₁-C₄ 烷氧基、C₁-C₄ 烷硫基和 C₁-C₄ 烷磺酰基;
R₃ 是氢或选自卤素、羟基、C₁-C₄ 烷基、三卤代-C₁-C₄ 烷基、C₁-C₄ 烷氧基、C₁-C₄ 烷硫基和 C₁-C₄ 烷磺酰基的取代基;
R₄ 是 -OR₅,或 -N(R₅ R₆)基团,其中 R₅ 和 R₆ 各自独立地是氢、C₁-C₆ 烷基、苯基或苄基;
及其药学上可接受的盐类,可用于治疗 TxA₂合成增强产生致病作用的疾病。